Page 2 - Peter Boonen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Key Capital Corporation: Key Capital Leads Oral Pill Vaccines Race with Immunitor Partnering and Strong Patenting NEW YORK, NY / ACCESSWIRE / March 3, 2021 / KEY CAPITAL CORPORATION (OTC PINK:KCPC) in response to recent global media coverage of a scramble or race to develop oral pill vaccines for disease treatment and/or for application to viruses including SARS-CoV-2, advises that, Immunitor, its Licensor and Partner is well recognized globally as a pioneer in oral vaccines development. Immunitor has been researching and developing oral pill vaccines for over two decades and has reported gam...

Press release content from Accesswire. The AP news staff was not involved in its creation. Key Capital Strengthens Vaccine Patents February 18, 2021 GMT Full Patent for Immunitor issued in China and EU Claims being re-filedNEW YORK, NY / ACCESSWIRE / February 18, 2021 / KEY CAPITAL CORPORATION (OTC PINK:KCPC) advises that it continues to work with Immunitor, its partner and Licensor, to progress ... Full Patent for Immunitor issued in China and EU Claims being re-filedNEW YORK, NY / ACCESSWIRE / February 18, 2021 / KEY CAPITAL CORPORATION (OTC PINK:KCPC) advises that it continues to work with...

Key Capital Corporation: Key Capital Strengthens Vaccine Patents Full Patent for Immunitor issued in China and EU Claims being re-filed NEW YORK, NY / ACCESSWIRE / February 18, 2021 / KEY CAPITAL CORPORATION (OTC PINK:KCPC) advises that it continues to work with Immunitor, its partner and Licensor, to progress further research and development of its breakthrough therapeutic vaccines, and for several unique supplements. PATENTS - Expanding Global Protection Key Capital, through its partnering and funding commitment with Immunitor recently finalized full patent filing in China, where local juri...

Key Capital Corporation: Key Capital to Distribute Novel Immune Supplement Promising Oral Pill Therapeutic Proposed to be Marketed as a Supplement NEW YORK, NY / ACCESSWIRE / January 28, 2021 / KEY CAPITAL CORPORATION (OTC Pink:KCPC) advises that as SARS-CoV-2 continues to spread, and reports of increases in daily infections, hospitalizations, and deaths are becoming regular, Key Capital plans to market its Immunitor partnered potentially therapeutic oral pill as a supplement commencing early February. Immunitor's proprietary and novel HapV+ ionic magnesium supplement, coupled with the patent...

Key Capital Corporation: Key Capital COVID-19 Oral Pill Vaccine Records 90% Reduction in Virus Infectivity in Early Study NEW YORK, NY / ACCESSWIRE / January 18, 2021 / KEY CAPITAL CORPORATION (OTC PINK:KCPC) is pleased to advise that current independent laboratory testing of its partnered Immunitor COVID-19 patented oral pill vaccine in an ongoing university study is providing promising early support for safety and efficacy of the vaccine. The preliminary tests conducted by a leading Asian research institute have shown safety and a 90% reduction on virus infectivity in mammalian cells follow...